-
British Museum bans photos of Bayeux Tapestry as crowds linger
-
US networks halt Trump coverage over White House ban
-
COP31 host says AI climate footprint to be a summit priority
-
French singer accuses Miley Cyrus of plagiarism
-
Berlin's far-left vote winners reject anti-semitism charges
-
EU fines Google 403 mn euros for location data breach
-
Mancini eager for 'new adventure' on Italy return
-
'Best is yet to come,' says De la Fuente after Spain extension
-
Mbappe says having Zidane as France coach 'like a film'
-
Why diesel prices are rising more than crude oil
-
Palmer, Rice out of England Nations League squad
-
COP31 host says AI's climate footprint to be a summit priority
-
German auto workers stage mass protests in bid to save jobs
-
Renewables hit record in 2025, but world must move faster: report
-
Embattled Merz vows to keep ruling for 'democratic future' of Germany
-
US media outlets to sue Trump administration after White House ban
-
Merz vows to keep ruling coalition together for 'democratic future' of Germany
-
Global stocks rally on lower oil prices, US-China hopes
-
Spain coach De la Fuente gets new deal after World Cup success
-
EU proposes energy rating for data centres
-
Pressure grows on Germany's Merz after election defeats
-
Schoolgirl Yu scorches to second gold as doping case rocks Games
-
China's Zhang beats Japan rivals to Asian Games gymnastics gold
-
Putin's party secures record score in Russia election
-
Samlingen Haupt: Vad pengar avslöjar om oss människor
-
Haupt Koleksiyonu: Paranın Biz İnsanlar Hakkında Anlattıkları
-
Tens of thousands of German auto workers protest to save jobs
-
Spanish PM says unregulated AI could be 'devastating'
-
हॉप्त् कलेक्शन: पैसा हमारे बारे में एक इंसान के रूप में क्या प्रकट करता है
-
Yu, 13, smashes record again with second Asian Games gold
-
Συλλογή Haupt: Τι αποκαλύπτει το χρήμα για εμάς τους ανθρώπους
-
Switzerland to play without Xhaka over fake Covid certificate
-
TradersYard Shifts Focus to Futures Trading
-
From Korean Chipmakers to Leveraged Semiconductor ETFs: STARTRADER Launches 49 New 24/7 Stock and ETF CFDs
-
ハウプト・コレクション:お金が人間について明かすこと
-
Thai badminton player first doping case at Asian Games: testers
-
하우프트 컬렉션: 돈이 우리 인간에 대해 드러내는 것
-
Колекція Гаупта: Що гроші розповідають про нас, людей
-
Indonesia doing 'everything' but struggling to curb fires
-
German far-right AfD poll winner says Merz 'twilight' has begun
-
Sbírka Haupt: Co o nás lidech prozrazují peníze
-
Flights scrapped, evacuations urged as Typhoon Dujuan nears Japan
-
North and South Korea fight out draw in niggly Asian Games clash
-
China confirms Xi to visit US this week for Trump talks
-
Officials say man shot, wounded by ICE agent in Texas
-
مجموعة هاوبت: ما يكشفه المال عنا نحن البشر
-
豪普特收藏:金錢如何揭露人類的本質
-
Colecția Haupt: Ce ne dezvăluie banii despre noi, oamenii
-
Kolekcja Haupta: Co pieniądze mówią o nas, ludziach
-
Sisters of jailed Pakistan ex-PM Imran Khan arrested
US House votes for life-changing $35 insulin price cap
US lawmakers voted Thursday on a bill limiting the cost of insulin to $35 a month, a transformative curb for millions of diabetics who pay hundreds of dollars for the life-sustaining hormone.
Drug pricing has vexed politicians for years in the United States, which has the highest annual health expenditure of any industrialized country, at around $11,000 per capita.
Insulin costs the 7.4 million American adults who use it to manage their diabetes eight times as much as in other wealthy nations, according to a 2020 study commissioned by the Health and Human Services Department.
"This is a kitchen table issue: are people going to be able to pay their bills? And it is, for us, a step in the direction of the (government) being able to negotiate for lower drug prices beyond insulin," House Speaker Nancy Pelosi told reporters.
The legislation passed the House of Representatives by 232 votes to 193, with a handful of Republicans crossing the aisle to join the Democrats, and now advances to the upper chamber of Congress, the US Senate.
It would require private health insurance companies to set prices for a month's supply of insulin at no more than $35, or 25 percent of a plan's negotiated price, whichever is lower, starting in 2023 for some patients and 2024 for all.
The cap was a provision in President Joe Biden's "Build Back Better" social welfare bill that was torpedoed by Democratic infighting in Congress late last year.
Biden brought the issue back into the spotlight during his State of the Union address on March 1, reinvigorating calls for action on pricing from diabetes advocates.
The effort is being seen as the only way for Democrats to show they're capable of acting on sky-high prescription drug prices before November's midterm elections.
- 'Costing a lot' -
The Senate is holding its own cross-party negotiations on driving down insulin costs by targeting the middlemen between health insurance companies and pharmacies.
And a separate Democrat-only bill from Georgia's Senator Raphael Warnock that would also cap the price at $35 is likely to be combined with the effort.
"I'm a pastor -- I'm on the ground -- and so I know that everybody knows somebody with diabetes," Warnock said in a video promoting his initiative.
Senate Majority Leader Chuck Schumer told reporters last week he believed a bipartisan bill had a good chance of passing when lawmakers return from a break at the end of April.
Research suggests that more than a quarter of Americans with type 1 diabetes have had to ration insulin they could not afford. Campaigners say the proportion went up to 50 percent during the pandemic.
It remains unclear if any legislation can gain the 10 Republican votes needed to advance in the Senate, but some opposition lawmakers have shown interest in an issue that affects voters across the board.
"I'd be for some kind of regulation where we can help. Too many people (are) paying thousands of dollars a month. I'm not big on regulating process, but that one's costing a lot of people a lot of money," Alabama Senator Tommy Tuberville told Axios.
Republicans on the powerful House Ways and Means Committee described the vote as "the largest expansion of federal command and control in Americans' private health insurance design" since the Affordable Care Act, the landmark 2010 regulatory overhaul and expansion of health care coverage.
"Democrats are reviving their socialist drug pricing scheme from their failed radical tax and spending spree," the committee's top Republican Kevin Brady said in a statement.
J.Bergmann--BTB